Overview
Probiodrug's drug development approach is based on the Company's comprehensive expertise of enzymes involved in the maintenance of peptide and protein hormones. Limited proteolysis or posttranslational modification is usually the last step in the maturation of hormones and therefore an important process for the regulation of hormones in the body.
Probiodrug has developed two novel therapeutic approaches, one based on inhibiting the enzyme Glutaminyl Cyclase (QC), the other based on inhibiting the enzyme Cyclin-Dependent Kinase 9 (CDK9). QC is a metalloenzyme involved in peptide hormone final maturation, an important step in many physiological and pathological processes, such as inflammation and Alzheimer’s disease (AD). CDK9, a cyclin-dependent kinase, is involved in cell cycle control and transcription regulation and, among others, involved in the regulation of immune responses and inflammation.
In Alzheimer’s disorder, Probiodrug’s expertise in metabolic enzymes has led to the discovery of an entirely new mechanism of action which is involved in the seeding of the typical depositions found in the brain of AD patients and also explains their neurotoxicity.
Learn more about > Probiodrug’s new paradigm in AD